Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease

This review examines the potential use of anti-amyloid-β monoclonal antibody therapies in individuals with Down syndrome who develop Alzheimer's disease, which is currently precluded by treatment guidelines. The authors highlight that persons with Down syndrome have distinct biological characteristics including blood-brain barrier differences, altered immune function, and elevated cerebral amyloid angiopathy, suggesting increased risks from these therapies that warrant further research.